CTLA4 and melanoma: PD-1/PD-L1 and CTLA-4 antibodies, which are representative of immune checkpoint inhibitors (ICIs), are considered to be revolutionary advances in oncology and have been approved by the US Food and Drug Administration (FDA) for the treatment of malignant melanoma, lung cancer, liver cancer, gastric cancer, urothelial cancer and lymphoma (78).